- Intensive blood pressure-lowering therapy reduced episodes of low blood pressure while standing, which may cause dizziness and increased risk of falling.
- Findings support value and safety achieving lower blood pressure in adults as way to mitigate cardiovascular risk.
Embargoed until 3 p.m. CT / 4 p.m. ET Saturday, Sept. 7, 2019
NEW ORLEANS, Sept. 7, 2019 — Adults who received more intensive treatment to lower their blood pressure were less likely to experience drastic blood pressure drops, which can cause dizziness and increase risk of falling, according to preliminary research presented at the American Heart Association’s Hypertension 2019 Scientific Sessions.
The study of more than 2,800 adults, average age 63 with a recent stroke, found that a lower systolic blood pressure goal was associated with a lower risk of sudden drops in blood pressure when changing position from sitting to standing — a condition known as orthostatic hypotension (OH). Systolic blood pressure is the top number in a blood pressure reading and a marker of the force of blood flow against the arteries when the heart contracts.
Optimal blood pressure helps reduce the risk for heart attacks and strokes, however, aggressive blood pressure treatment in older adults has long been thought to contribute to falls. Falling is a well-known risk factor for fractures, prolonged hospitalization and even death in older individuals. One in four older adults experience a fall each year, according to the National Council on Aging.
“Falls can be devastating in this older population,” said lead study author Stephen Juraschek, M.D., Ph.D., an assistant professor of medicine at Harvard Medical School and an internal medicine physician at Beth Israel Deaconess Medical Center in Boston, Mass. “As a result, there is substantial concern about anything that might increase their fall risk. However, our study provides strong evidence that intense blood pressure treatment does not induce orthostatic hypotension or its symptoms.”
Previous studies have yielded inconclusive evidence, the researchers said. In this study, Juraschek and team set out to determine how lower systolic blood pressure affects symptoms of OH.
The researchers monitored response to blood pressure medication in two groups of patients. Half of the participants were treated more aggressively, aiming to reduce blood pressure to levels below 130/80 mmHg. The other half received less intensive therapy allowing them to maintain a slightly higher blood pressure of between 130-149/80-90 mmHg or more.
Researchers monitored blood pressure levels and symptoms during 36,342 visits, for an average of 15 visits per participant. During each visit, a participant’s blood pressure was measured three times while seated and one time after two minutes of standing up to capture any changes and symptoms of OH.
Participants who received more intensive therapy and achieved lower systolic blood pressure (130 mm/Hg or under) had better overall blood pressure control and had fewer OH episodes.
Co-authors included Jennifer Beach, M.D.; Anthony Ishak, Pharm.D.; and Kenneth Mukamal, M.D., MPH. The authors indicate in the abstract that they have no disclosures to report.
The work was funded by a National Institutes of Health grant.
- Available multimedia is on the right column of the release link
- A study of fainting astronauts could provide help for the earthbound, too Follow AHA/ASA news on Twitter @HeartNews #Hypertension19
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect Association policy or position. The Association makes no representation or warranty as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective: 214-706-1173
Cathy Lewis: 214-706-1324; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)